3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Pancreatic Neoplasms
43
Carcinoma, Non-Small-Cell Lung
35
Breast Neoplasms
35
Triple Negative Breast Neoplasms
16
Neoplasms
15
Neoplasm Metastasis
14
Carcinoma
9
Adenocarcinoma
9
Lung Neoplasms
7
Head and Neck Neoplasms
6
Colorectal Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Diseases
5
Cholangiocarcinoma
5
Carcinoma, Squamous Cell
5
Neoplasms by Site
4
Melanoma
4
Digestive System Neoplasms
4
Digestive System Diseases
4
Sarcoma
3
Pancreatic Adenocarcinoma
3
Neoplasms by Histologic Type
3
Inflammatory Breast Neoplasms
3
Endocrine System Diseases
3
Endocrine Gland Neoplasms
3
Carcinoma, Pancreatic Ductal
3
Carcinoma, Ovarian Epithelial
3
Uveal Melanoma
2
Urinary Bladder Neoplasms
2
Interventions
Nivolumab
4
pertuzumab
2
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Docetaxel
2
Capecitabine
2
ulocuplumab
1
tremelimumab
1
tazarotene
1
talazoparib
1
romiplostim
1
pexidartinib
1
pamiparib
1
onartuzumab
1
magrolimab
1
entrectinib
1
cobimetinib
1
atezolizumab
1
Sunitinib
1
Rifampin
1
Ramucirumab
1
Radiosurgery
1
N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
1
Midazolam
1
MK-4166
1
LY3022855
1
LY2510924
1
LY-2157299
1
Itraconazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Solid Tumor
×
130-nm albumin-bound paclitaxel
×
Clear all
No trials found.